Contact: to feature here

Thread Rating:
  • 0 Vote(s) - 0 Average
  • 1
  • 2
  • 3
  • 4
  • 5
Novartis International AG Latest News and Vacancies
Novartis International AG is a multinational pharmaceutical company based in Basel, Switzerland. Its world's second largest company and is worldwide famous for its innovative and high quality products. Novartis is a product of merger of two Swiss giants Ciba-Geigy and Sandoz laboratories, history of the company dates back to be as old as 250 years. It manufactures a range of medicines, some are based on chemical synthesis and some from fermentation. Company holds a strong reputation in Clinical trials too.

In this thread we will discuss about the great innovations and latest updates by the company.

Malaria is the most dreadful disease of all time. Scientists from different countries have given their best to get a permanent solution for it. But due to complicated intricacies of the infection mechanism a solution to eradicate it is yet awaited. But this time Novartis is all set to get us rid of the problem. They approached to propose a vaccine rather than a healing drug, which will help to solve the root cause. As we all know prevention is better than cure.

When it comes to working in different geographic conditions with people of different races and religion, undoubtedly Novartis leaves past many big companies. Diversity Inc conducts this free of cost survey based on CEO commitments, human capital, effectiveness of diversity management and supplier diversity. With its presence over six continents it is hard to imagine the list without Novartis.

With its increasing world popularity for high quality and highly effective medicines it has been heavily successful in winning everyone's heart for its endless effort to be best. Fortune, the most famous magazine, has listed it as one of the World's most admired company.
  • Next Generation Scientist Program

If you or any of your siblings/friends are one of the big science bee of the school definitely it has to be in your career record. This is the best thing that can happen to a science maniac which will not only provide insight into latest technologies but will also expose them with nitti-gritties practical science in an industrial scale. This video explains a lot of it.

  • Vacancies

Novartis due to its worldwide presence has vacancies in different countries in different divisions like QA, QC, R&D, Production, etc. Kindly go through the career site to select the destination of your choice.

[Image: nova.jpg]

We will keep you updated with latest news.
Kalpana Samant
Bioprocess Engineer & Freelancer
Like Post Reply

With great power comes great responsbility and Novartis is fully ready to deliver all it can to reach the poor and serve humanity. A big cheers to a great step taken by a great company.

8th July 2013, Novartis entered into an agreement with Biological-E to develop and deliver affordable and high quality vaccines to prevent against typhoid and paratyphoid fever. As per report development has taken five years, the Novartis Vaccines Institute for Global Health (NVGH), part of the Novartis Institutes for BioMedical Research, has developed it with funding by the Fondazione Monte dei Paschi di Siena and Regione Toscana through the Sclavo Vaccines Association (Italy). Designed vaccine is a dual-acting vaccine with components against both typhoid and paratyphoid fevers is being developed, a huge support from the Wellcome Trust is also projected. The prevention might help to bring quite a relief in the endemic regions like India, Sub-Saharan part etc.

Per year approx 21 million cases of typhoid fever and five million cases of paratyphoid A fever are reported worldwide, especially in areas that are yet to develop hygienic sanitation and clean drinking water. Victims are mainly children under the age of two for whom medicines and vaccines related to typhoid are not properly developed and tested, and as of now there is no vaccine is available for any age group against paratyphoid fever.

Why Biological-E and what do we expect from the partnership?

Biological-E is an India based vaccine development profile company and has a proven track record in addressing the economical problem by provider cheaper and better efficacy vaccines.

We should expect cheaper and high standard vaccines that can be supplied throughout the world other than developed countries.

BioE is working to reach World Health Organization (WHO) pre-qualification and fulfill specific obligations & standards to meet Novartis working and quality standards. The agreement is presently worldwide except for developed countries, where Novartis will retain its rights and production status.

Lets hope for more agreements like this in future, this will tremendously improve public status in developing countries.
Kalpana Samant
Bioprocess Engineer & Freelancer
Like Post Reply
Recent happenings in Novartis AG - August 2013

Novartis AG is focused by the media for various happenings in favor of the organization started right from the beginning of the month August 2013.

Vaccine Menveo

The quadrivalent vaccine Menveo, a product of Novartis gets nod from FDA for its use in the age groups starting from 2 month old babies since 1st of August 2013.

Vaccine: Menveo

Against: Meningococcal disease

First quadrivalent vaccine: It is effective against the disease caused by four strains like A, C,Y and W 135 of the bacterium Neisseria meningitides.

Following this on 8th of August 2013 Novartis was accredited by CEO Rountable on cancer which is a NGO.

Nature of Accreditation: Global CEO cancer Gold standard Accreditation

Salient features of this Accreditation

This accreditation is granted based on the organization’s commitment to protect its employees from cancer which requires several initiatives by the organization like

Providing the employees a healthy work place

Guiding the employees to adopt good life style practices which keep them away from cancer

Making cancer detection and cancer screening techniques available to the employees through the organization and if detected with cancer providing them the best treatment

And Novartis is the first to get accredited for ensuring all the guidelines required to get accredited by the CEO Rountable Cancer.

The Vaccine Bexsero

Next comes in the news the approval of the Bexsero vaccine a Novartis product for its use in Australia which was announced on 15th of August 2013 and this vaccine entered the ARTG list through TGA.

Bexsero: Vaccine against the devastating disease MenB.

Who can get this vaccine?
From the age of 2 months and above

Clinical Trials: Proved the safety and efficiency of the vaccine. Done on average of eight thousand people which comprised of the individuals from infants to adults

Discussion on the importance of including this vaccine in the National immunization Program is underway.
Like Post Reply

Possibly Related Threads…
Last Post
Replies: 3
Views: 24,031
02-18-2017, 05:29 PM
Last PostAbdul
Replies: 0
Views: 7,488
03-31-2016, 09:06 PM
Last PostHEL Group
Replies: 0
Views: 15,144
07-25-2015, 04:16 AM
Last Postgmshim
Replies: 1
Views: 17,792
03-26-2015, 04:12 PM
Last Postjuston33

Users browsing this thread:
1 Guest(s)

Novartis International AG Latest News and Vacancies00